Recommended 5-FU Chemoradiation Dose for Colorectal Cancer
For concurrent chemoradiation in colorectal cancer, use 5-FU as a continuous infusion at 225 mg/m²/day, administered 5-7 days per week throughout the entire radiotherapy course.
Standard Dosing Regimen
The most widely endorsed approach across multiple guidelines is:
- 5-FU continuous infusion: 225 mg/m²/day
- Schedule: 5-7 days per week during radiotherapy
- Duration: Throughout the entire radiation treatment period (typically 5-5.5 weeks)
- Radiation dose: 45.0-50.4 Gy in 25-28 fractions 1, 2, 1
This continuous infusion regimen is consistently recommended by both the most recent CSCO 2024 guidelines 1 and established NCCN guidelines 2.
Alternative Bolus Regimen
A less commonly used alternative is:
- 5-FU 400 mg/m² IV bolus + leucovorin 20 mg/m² IV bolus
- Schedule: Days 1-4 during weeks 1 and 5 of radiotherapy only 2
However, the continuous infusion approach is generally preferred due to more consistent drug exposure and potentially improved radiosensitization.
Key Clinical Considerations
Radiation therapy parameters:
- Standard pelvic dose: 45-50 Gy in 25-28 fractions (1.8-2.0 Gy per fraction)
- Tumor boost (if resectable): Additional 5.4 Gy/3 fractions preoperatively or 5.4-9.0 Gy/3-5 fractions postoperatively 1, 2
- Small bowel dose constraint: Maximum 45-50 Gy 1, 2
Important dosing pitfall: The NCCN specifically recommends limiting chemotherapy orders to 24-hour units (i.e., 1200 mg/m²/day NOT 2400 mg/m²/day over 46 hours) to minimize medication errors 2.
Capecitabine Alternative
For patients unable to receive continuous infusion 5-FU, capecitabine 825 mg/m² twice daily, 5 days per week during radiotherapy is an acceptable oral alternative 1, 2. This provides equivalent efficacy with the convenience of oral administration, though it is typically considered a Category 2B recommendation.
Timing of Surgery
Surgery should be performed 6-10 weeks after completing chemoradiation to allow for maximal tumor response and downstaging 3, 4. This interval is critical for achieving optimal pathologic complete response rates, which can reach 13-26% with this regimen 5, 3.
Evidence Strength
The continuous infusion 5-FU regimen at 225 mg/m²/day is supported by the most recent 2025 CSCO guidelines 1 and has been validated across multiple prospective studies showing significant tumor downstaging (42-62%), pathologic complete response rates (5-26%), and improved sphincter preservation rates (84-94%) in locally advanced rectal cancer 5, 3, 6, 4.